A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids

Abstract

Fomivirsen is an effective treatment for CMV retinitis in patients with AIDS that utilizes a mechanism of action different than that of ganciclovir, foscarnet, and cidofovir.

LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma

“…ASOs are an effective and feasible means of selectively targeting a gene of interest; four ASOs (fomivirsen, nusinersen, mipomersen, and eteplirsen) have already been approved by the FDA [ 40 , 41 , 42 , 43 ]. ASOs are known to cleave target RNA in both the cytoplasm and the nucleus, depending on RNase H1 [ 44 ].…”

LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma

“…ASOs are an effective and feasible means of selectively targeting a gene of interest; four ASOs (fomivirsen, nusinersen, mipomersen, and eteplirsen) have already been approved by the FDA [ 40 , 41 , 42 , 43 ]. ASOs are known to cleave target RNA in both the cytoplasm and the nucleus, depending on RNase H1 [ 44 ].…”

Approved Antiviral Drugs over the Past 50 Years

“…Fomivirsen sodium, administered as an intravitreal injection into human eyes, has been approved for treating HCMV retinitis in patients infected with AIDS (367). Despite the fact that it is well tolerated and has a favorable safety profile (368), intravitreous fomivirsen has been discontinued for commercial reasons.…”

Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

“…It exhibited a half-life of 78 h after intravitreal administration of 115 µg dose in monkeys [ 81 ]. Fomivirsen demonstrated clinical efficacy in a randomized clinical trial and delayed the progression of CMV infection in AIDS patients by 71 days as compared to 13 days in the deferred patient cohort [ 82 ]. However, the same period witnessed the success of the highly active antiretroviral therapy (HAART), which reduced the incidences of opportunistic inf-ections in AIDS patients and thus reduced market demand for Fomivirsen.…”

LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma

“…ASOs are an effective and feasible means of selectively targeting a gene of interest; four ASOs (fomivirsen, nusinersen, mipomersen, and eteplirsen) have already been approved by the FDA [ 40 , 41 , 42 , 43 ]. ASOs are known to cleave target RNA in both the cytoplasm and the nucleus, depending on RNase H1 [ 44 ].…”

Approved Antiviral Drugs over the Past 50 Years

“…Fomivirsen sodium, administered as an intravitreal injection into human eyes, has been approved for treating HCMV retinitis in patients infected with AIDS (367). Despite the fact that it is well tolerated and has a favorable safety profile (368), intravitreous fomivirsen has been discontinued for commercial reasons.…”

Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

“…It exhibited a half-life of 78 h after intravitreal administration of 115 µg dose in monkeys [ 81 ]. Fomivirsen demonstrated clinical efficacy in a randomized clinical trial and delayed the progression of CMV infection in AIDS patients by 71 days as compared to 13 days in the deferred patient cohort [ 82 ]. However, the same period witnessed the success of the highly active antiretroviral therapy (HAART), which reduced the incidences of opportunistic inf-ections in AIDS patients and thus reduced market demand for Fomivirsen.…”

LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma

“…ASOs are an effective and feasible means of selectively targeting a gene of interest; four ASOs (fomivirsen, nusinersen, mipomersen, and eteplirsen) have already been approved by the FDA [ 40 , 41 , 42 , 43 ]. ASOs are known to cleave target RNA in both the cytoplasm and the nucleus, depending on RNase H1 [ 44 ].…”

Approved Antiviral Drugs over the Past 50 Years

“…Fomivirsen sodium, administered as an intravitreal injection into human eyes, has been approved for treating HCMV retinitis in patients infected with AIDS (367). Despite the fact that it is well tolerated and has a favorable safety profile (368), intravitreous fomivirsen has been discontinued for commercial reasons.…”

Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

“…It exhibited a half-life of 78 h after intravitreal administration of 115 µg dose in monkeys [ 81 ]. Fomivirsen demonstrated clinical efficacy in a randomized clinical trial and delayed the progression of CMV infection in AIDS patients by 71 days as compared to 13 days in the deferred patient cohort [ 82 ]. However, the same period witnessed the success of the highly active antiretroviral therapy (HAART), which reduced the incidences of opportunistic inf-ections in AIDS patients and thus reduced market demand for Fomivirsen.…”